Beam Therapeutics (BEAM) Return on Capital Employed (2020 - 2026)
Beam Therapeutics' (BEAM) quarterly Return on Capital Employed came in at 26.42% in Q1 2026, up 1123.0% year-on-year from 2.16% in Q1 2025, and up 10.53% on a QoQ basis from 29.53% in Q4 2025.
Beam Therapeutics (BEAM) Return on Capital Employed (2020 - 2026) Analysis & Trends
Beam Therapeutics (BEAM) has 7 years of Return on Capital Employed data on file, last reported at 26.42% in Q1 2026.
- On a quarterly basis, Return on Capital Employed rose 1123.0% year-over-year to 26.42% in Q1 2026; TTM through Mar 2026 was 26.42%, a 1123.0% increase from a year earlier, with the FY2025 full-year figure at 32.09%, up 570.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 26.42%, up from 29.53% in the prior quarter.
- Over the last five years, Return on Capital Employed for BEAM reached as high as 14.86% in Q1 2024 and fell as low as 43.49% in Q4 2024.
- Historically, Return on Capital Employed has averaged 28.3% across 5 years, with a median of 29.53% in 2025.
- Across the five-year window, Return on Capital Employed soared 4325 bps in 2022 and plunged 2840 bps in 2024, its largest moves.
- Year by year, Return on Capital Employed stood at 30.16% in 2022, then jumped by 50 bps to 15.09% in 2023, then slumped by 188 bps to 43.49% in 2024, then jumped by 32 bps to 29.53% in 2025, then grew by 11 bps to 26.42% in 2026.
- Per Business Quant data, the three most recent Return on Capital Employed figures were 26.42% in Q1 2026, 29.53% in Q4 2025, and 39.9% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Beam Therapeutics | 2.68 Bn | 2.68 Bn | - | -26.42% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -26.42% |
| Dec 31, 2025 | -29.53% |
| Sep 30, 2025 | -39.90% |
| Jun 30, 2025 | -35.54% |
| Mar 31, 2025 | -37.66% |
| Dec 31, 2024 | -43.49% |
| Sep 30, 2024 | -17.40% |
| Jun 30, 2024 | -16.28% |
| Mar 31, 2024 | -14.86% |
| Dec 31, 2023 | -15.09% |
| Sep 30, 2023 | -36.15% |
| Jun 30, 2023 | -33.64% |
| Mar 31, 2023 | -32.33% |
| Dec 31, 2022 | -30.16% |
| Sep 30, 2022 | -27.32% |
| Jun 30, 2022 | -23.81% |
| Mar 31, 2022 | -21.55% |
| Dec 31, 2021 | -35.61% |
| Sep 30, 2021 | -40.04% |
| Jun 30, 2021 | -50.79% |